## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 8)\*

BioTime, Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

09066L105

(CUSIP Number)

April 17, 2002

(Date of Event which Requires Filing this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box [ ].

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 09066L105

- Names of Reporting Persons S.S. or I.R.S. Identification Nos. of Above Persons Paul Segall
- 3) SEC Use Only
- Source of Funds (See Instructions) PF; 00
- 5) Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
- Citizenship or Place of Organization U.S.A.

0

Number of Shares Beneficially Owned by Each Reporting Person With	7)	Sole Voting Power 343,245
	8)	Shared Voting Power 0
	9)	Sole Dispositive Power 343,245
	10)	Shared Dispositive Power

- 11) Aggregate Amount Beneficially Owned by Each Reporting Person 545,408
- 12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
  [ ]
- 13) Percent of Class Represented by Amount in Row (11) \$4.69%
- 14) Type of Reporting Person (See Instructions) IN

Page 2 of 4 Pages

CUSIP No.	0906	9066L105			
	1)	Names of Reporting Persons S.S. or I.R.S. Identification Nos. of Above Persons Judith Segall			
	2)	Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ]			
	3)	SEC Use Only			
	4)	Source of Funds (See Instructions) PF; 00			
5)		Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]			
6 Number of Shares Beneficiall Owned by Each Reporting Person With	6)	Citizenship or Place of Organization U.S.A.			
	:	7) Sole Voting Power 202,163			
	lly	8) Shared Voting Power 0			
		9) Sole Dispositive Power 202,163			
		10) Shared Dispositive Power 0			
11) 12)		Aggregate Amount Beneficially Owned by Each Reporting Person 545,408			
		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ]			
	13)	Percent of Class Represented by Amount in Row (11) 4.69%			

14) Type of Reporting Person (See Instructions) IN

Page 3 of 4 Pages

## Item 1. Security and Issuer

The class of equity securities to which this schedule relates is Common Shares, no par value (the "Common Shares"), of BioTime, Inc., a California corporation (the "Company"). The Company has its principal executive offices at 935 Pardee Street, Berkeley, California 94710.

This schedule is being filed pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations promulgated thereunder.

Item 4. Interest in Securities of the Issuer

In order to reduce the amount of his margin indebtedness, on April 17, 2002 Paul Segall sold 100,000 Common Shares to Alfred D. Kingsley for \$2.50 per share, in a privately negotiated transaction. Paul Segall now directly owns 343,245 Common Shares, which constitute approximately 2.95% of the 11,627,316 Common Shares outstanding on March 7, 2002. Judith Segall directly owns 202,163 Common Shares, which constitute approximately 1.7% of the 11,627,316 Common Shares outstanding on March 7, 2002. The Common Shares owned by Mr. and Mrs. Segall in the aggregate constitute approximately 4.69% of the 11,627,316 Common Shares outstanding on March 7, 2002. The forgoing number of outstanding Common Shares is based upon information provided by the Company in its Annual Report on Form 10-K for the year ending December 31, 2001, as filed with the Securities and Exchange Commission.

## Signature

After reasonable inquiry and to the best of our knowledge we certify that the information set forth in the statement is true, complete and correct.

Dated: April 18, 2002

/s/ Paul Segall Paul Segall

Dated: April 18, 2002

/s/ Judith Segall Judith Segall

Page 4 of 4 Pages